Cardiac NO signalling in the metabolic syndrome

British Journal of Pharmacology

Volumn 172, Issue 6, 2015, Pages 1415-1433

  Pechanova O ^a,b   Varga, Z V ^c   Cebova M ^a   Giricz, Z ^c   Pacher, P ^d   Ferdinandy, P ^c,e  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^e PHARMAHUNGARY GROUP   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ASCORBIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HYDROXYTYROSOL; INDUCIBLE NITRIC OXIDE SYNTHASE; LA 419; MELATONIN; MOLSIDOMINE; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE DONOR; OLEUROPEIN; PENTAERYTHRITYL TETRANITRATE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; POLYPHENOL DERIVATIVE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RESVERATROL; SILDENAFIL; TADALAFIL; TEMPOL; UNCLASSIFIED DRUG; VARDENAFIL; CELL RECEPTOR; SOLUBLE GUANYLYL CYCLASE;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA STENOSIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CELLULAR DISTRIBUTION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; GLYCEMIC CONTROL; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID STORAGE; METABOLIC SYNDROME X; NITRATIVE STRESS; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; VASODILATATION; ANIMAL; CARDIAC MUSCLE; COMPLICATION; DRUG DESIGN; METABOLISM; PHYSIOLOGY;

ANIMALS; DRUG DESIGN; GUANYLATE CYCLASE; HUMANS; METABOLIC SYNDROME X; MYOCARDIUM; NITRIC OXIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84923781545     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12960     Document Type: Review

References (220)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013e). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170: 1652-1675.
6. Almansob MA, Xu B, Zhou L, Hu XX, Chen W, Chang FJ, et al. (2012). Simvastatin reduces myocardial injury undergoing noncoronary artery cardiac surgery: a randomized controlled trial. Arterioscler Thromb Vasc Biol 32: 2304-2313.
7. Alvarez GE, Beske SD, Ballard TP, Davy KP, (2002). Sympathetic neural activation in visceral obesity. Circulation 106: 2533-2536.
8. Amour J, Loyer X, Le Guen M, Mabrouk N, David JS, Camors E, et al. (2007). Altered contractile response due to increased beta3-adrenoceptor stimulation in diabetic cardiomyopathy: the role of nitric oxide synthase 1-derived nitric oxide. Anesthesiology 107: 452-460.
9. 2S, CO in myocardial ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Br J Pharmacol 172: 1587-1606.
10. Ansley DM, Wang B, (2013). Oxidative stress and myocardial injury in the diabetic heart. J Pathol 229: 232-241.
11. Aroor AR, Sowers JR, Bender SB, Nistala R, Garro M, Mugerfeld I, et al. (2013). Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology 154: 2501-2513.
12. Azevedo PS, Minicucci MF, Santos PP, Paiva SA, Zornoff LA, (2013). Energy metabolism in cardiac remodeling and heart failure. Cardiol Rev 21: 135-140.
13. Babal P, Pechanova O, Bernatova I, Stvrtina S, (1997). Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia. Histol Histopathol 12: 623-629.
14. Bagi Z, Koller A, Kaley G, (2004). PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol 286: H742-H748.
15. Baraka A, Mikhail M, Guemei A, El Ghotny S, (2009). Effect of targeting mitogen-activated protein kinase on cardiac remodeling in rats. J Cardiovasc Pharmacol Ther 14: 339-346.
16. Belin de Chantemele EJ, Stepp DW, (2012). Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation. J Mol Cell Cardiol 52: 840-847.
17. Belmonte S, Morad M, (2008). Pressure-flow'-triggered intracellular Ca2+ transients in rat cardiac myocytes: possible mechanisms and role of mitochondria. J Physiol 586: 1379-1397.
18. Borghi C, Cicero AF, Ambrosioni E, (2008). Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag 4: 665-671.
19. Bouvet C, Belin de Chantemele E, Guihot AL, Vessières E, Bocquet A, Dumont O, et al. (2007). Flow-induced remodeling in resistance arteries from obese Zucker rats is associated with endothelial dysfunction. Hypertension 50: 248-254.
20. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. (1998). Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98: 1842-1847.
21. Bulhak AA, Jung C, Ostenson CG, Lundberg JO, Sjöquist PO, Pernow J, (2009). PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol 296: H719-H727.
22. Burley DS, Cox CD, Zhang J, Wann KT, Baxter GF, (2014). Natriuretic peptides modulate ATP-sensitive K(+) channels in rat ventricular cardiomyocytes. Basic Res Cardiol 109: 402.
23. Carvalheira JB, Siloto RM, Ignacchitti I, Brenelli SL, Carvalho CR, Leite A, et al. (2001). Insulin modulates leptin-induced STAT3 activation in rat hypothalamus. FEBS Lett 500: 119-124.
24. Cebova M, Kristek F, (2011). Age-dependent ultrastructural changes of coronary artery in spontaneously hypertensive rats. Gen Physiol Biophys 30: 364-372.
25. Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, Zhang L, et al. (2007). Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 71: 144-152.
26. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, et al. (2001). A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813-822.
27. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, et al. (2005). Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96: 225-233.
28. Chobanyan-Jürgens K, Fuchs AJ, Tsikas D, Kanzelmeyer N, Das AM, Illsinger S, et al. (2012). Increased asymmetric dimethylarginine (ADMA) dimethylaminohydrolase (DDAH) activity in childhood hypercholesterolemia type II. Amino Acids 43: 805-811.
29. Chrysant SG, Chrysant GS, (2012). The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. J Clin Hypertens 14: 644-649.
30. Coatmellec-Taglioni G, Ribière C, (2003). Factors that influence the risk of hypertension in obese individuals. Curr Opin Nephrol Hypertens 12: 305-308.
31. Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, et al. (2012). Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol 3: 128.
32. Csonka C, Szilvássy Z, Fülöp F, Páli T, Blasig IE, Tosaki A, et al. (1999). Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts. Circulation 100: 2260-2266.
33. Csonka C, Csont T, Onody A, Ferdinandy P, (2001). Preconditioning decreases ischemia/reperfusion-induced peroxynitrite formation. Biochem Biophys Res Commun 285: 1217-1219.
34. Csonka C, Pali T, Bencsik P, Gorbe A, Ferdinandy P, Csont T, (2015). Measurement of NO in biological samples. Br J Pharmacol 172: 1620-1632.
35. Csont T, Ferdinandy P, (2005). Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol Ther 105: 57-68.
36. Csont T, Bereczki E, Bencsik P, Fodor G, Görbe A, Zvara A, et al. (2007). Hypercholesterolemia increases myocardial oxidative and nitrosative stress thereby leading to cardiac dysfunction in apoB-100 transgenic mice. Cardiovasc Res 76: 100-109.
37. Cuspidi C, Ciulla M, Zanchetti A, (2006). Hypertensive myocardial fibrosis. Nephrol Dial Transplant 21: 20-23.
38. Dai Z, Wu Z, Yang Y, Wang J, Satterfield MC, Meininger CJ, et al. (2013). Nitric oxide and energy metabolism in mammals. Biofactors 39: 383-391.
39. Davidson SM, Duchen MR, (2006). Effects of NO on mitochondrial function incardiomyocytes: pathophysiological relevance. Cardiovasc Res 71: 10-21.
40. Dedkova EN, Blatter LA, (2009). Characteristics and function of cardiac mitochondrial nitric oxide synthase. J Physiol 587 (Pt 4): 851-872.
41. Desrois M, Clarke K, Lan C, Dalmasso C, Cole M, Portha B, et al. (2010). Upregulation of eNOS and unchanged energy metabolism in increased susceptibility of the aging type 2 diabetic GK rat heart to ischemic injury. Am J Physiol Heart Circ Physiol 299: H1679-H1686.
42. Dikalov S, Skatchkov M, Bassenge E, (1997). Quantification of peroxynitrite, superoxide, and peroxyl radicals by a new spin trap hydroxylamine 1-hydroxy-2,2,6,6-tetramethyl-4-oxopiperidine. Biochem Biophys Res Commun 230: 54-57.
43. Dikalov S, Fink B, Skatchkov M, Sommer O, Bassenge E, (1998). Formation of reactive oxygen species by pentaerithrityl tetranitrate and glyceryl trinitrate in vitro and development of nitrate tolerance. J Pharmacol Exp Ther 286: 938-944.
44. Dikalov S, Fink B, Skatchkov M, Bassenge E, (1999). Comparison of glyceryl trinitrate-induced with pentaerythrityl tetranitrate-induced in vivo formation of superoxide radicals: effect of vitamin C. Free Radic Biol Med 27: 170-176.
45. Dikalov SI, Ungvari Z, (2013). Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol 305: H1417-H1427.
46. Ding H, Aljofan M, Triggle CR, (2007). Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. J Cell Physiol 212: 682-689.
47. Dröge W, (2002). Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95.
48. Duffy SJ, Gokce N, Holbrook M, Huang A, Frei B, Keaney JF Jr, et al. (1999). Treatment of hypertension with ascorbic acid. Lancet 354: 2048-2049.
49. Ebenezer PJ, Mariappan N, Elks CM, Haque M, Francis J, (2009). Diet-induced renal changes in Zucker rats are ameliorated by the superoxide dismutase mimetic TEMPOL. Obesity 17: 1994-2002.
50. Esberg LB, Ren J, (2003). Role of nitric oxide, tetrahydrobiopterin and peroxynitrite in glucose toxicity-associated contractile dysfunction in ventricular myocytes. Diabetologia 46: 1419-1427.
51. Evgenov OV, Pacher P, Schmidt PM, Haskõ G, Schmidt HH, Stasch JP, (2006). NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755-768.
52. Farhangkhoee H, Khan ZA, Mukherjee S, Cukiernik M, Barbin YP, Karmazyn M, et al. (2003). Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 35: 1439-1448.
53. Ferdinandy P, (2006). Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well? Br J Pharmacol 148: 1-3.
54. Ferdinandy P, Schulz R, (2003). Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 138: 532-543.
55. Ferdinandy P, Szilvássy Z, Horváth LI, Csont T, Csonka C, Nagy E, et al. (1997). Loss of pacing-induced preconditioning in rat hearts: role of nitric oxide and cholesterol-enriched diet. J Mol Cell Cardiol 29: 3321-3333.
56. Feron O, Balligand JL, (2006). Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 69: 788-797.
57. Fiordaliso F, De Angelis N, Bai A, Cuccovillo I, Salio M, Maria SD, et al. (2007). Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats. Life Sci 81: 951-959.
58. Frohlich ED, Susic D, (2008). Mechanisms underlying obesity associated with systemic and renal hemodynamics in essential hypertension. Curr Hypertens Rep 10: 151-155.
59. Frühbeck G, (1999). Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 48: 903-908.
60. Fukuda M, Nakamura T, Kataoka K, Nako H, Tokutomi Y, Dong YF, et al. (2010). Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice. J Pharmacol Exp Ther 335: 70-75.
61. Fukuda Y, Teragawa H, Matsuda K, Yamagata T, Matsuura H, Chayama K, (2002). Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart 87: 264-269.
62. Fulton D, Harris MB, Kemp BE, Venema RC, Marrero MB, Stepp DW, (2004). Insulin resistance does not diminish eNOS expression, phosphorylation, or binding to HSP-90. Am J Physiol Heart Circ Physiol 287: H2384-H2393.
63. Galleano M, Pechanova O, Fraga CG, (2010). Hypertension, nitric oxide, oxidants, and dietary plant polyphenols. Curr Pharm Biotechnol 11: 837-848.
64. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, et al. (2002). Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105: 1497-1502.
65. Garcia JA, dos Santos L, Moura AL, Ricardo KF, Wanschel AC, Shishido SM, et al. (2008). S-nitroso-N-acetylcysteine (SNAC) prevents myocardial alterations in hypercholesterolemic LDL receptor knockout mice by antiinflammatory action. J Cardiovasc Pharmacol 51: 78-85.
66. Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, Sessa WC, (1996). Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci U S A 93: 6448-6453.
67. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr, (1999). Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33: 119-124.
68. Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, Hucke A, et al. (2011). Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS ONE 6: e21853.
69. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. (2013a). PATENT-1 Study group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369: 330-340.
70. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. (2013b). CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369: 319-329.
71. Gielis JF, Lin JY, Wingler K, Van Schil PE, Schmidt HH, Moens AL, (2011). Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radic Biol Med 50: 765-776.
72. Giricz Z, Csonka C, Onody A, Csont T, Ferdinandy P, (2003). Role of cholesterol-enriched diet and the mevalonate pathway in cardiac nitric oxide synthesis. Basic Res Cardiol 98: 304-310.
73. Giricz Z, Görbe A, Pipis J, Burley DS, Ferdinandy P, Baxter GF, (2009). Hyperlipidaemia induced by a high-cholesterol diet leads to the deterioration of guanosine-3,5-cyclic monophosphate/protein kinase G-dependent cardioprotection in rats. Br J Pharmacol 158: 1495-1502.
74. Gonon AT, Bulhak A, Labruto F, Sjöquist PO, Pernow J, (2007). Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol 102: 80-89.
75. Gross ER, LaDisa JF Jr, Weihrauch D, Olson LE, Kress TT, Hettrick DA, et al. (2003). Reactive oxygen species modulate coronary wall shear stress and endothelial function during hyperglycemia. Am J Physiol Heart Circ Physiol 284: H1552-H1559.
76. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, et al. (2009). Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 104: 403-411.
77. Habibi J, Whaley-Connell A, Qazi MA, Hayden MR, Cooper SA, Tramontano A, et al. (2007). Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology 148: 2181-2188.
78. Han J, Kim N, Joo H, Kim E, Earm YE, (2002). ATP-sensitive K(+) channel activation by nitric oxide and protein kinase G in rabbit ventricular myocytes. Am J Physiol Heart Circ Physiol 283: H1545-H1554.
79. Han L, Li M, Liu Y, Han C, Ye P, (2012). Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats. Pharmacology 89: 74-82.
80. Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M, (2002). Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 61: 586-590.
81. Hasegawa T, Okada K, Okita Y, Pinsky DJ, (2011). Antioxidant properties of pioglitazone limit nicotinamide adenine dinucleotide phosphate hydrogen oxidase and augment superoxide dismutase activity in cardiac allotransplantation. J Heart Lung Transplant 30: 1186-1196.
82. Hayashi H, Kobara M, Abe M, Tanaka N, Gouda E, Toba H, et al. (2008). Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res 31: 363-375.
83. van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, et al. (2012). Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126: 830-839.
84. Herring N, Lee CW, Sunderland N, Wright K, Paterson DJ, (2011). Pravastatin normalises peripheral cardiac sympathetic hyperactivity in the spontaneously hypertensive rat. J Mol Cell Cardiol 50: 99-106.
85. Heusch G, (2001). Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug? Circulation 103: 2876-2878.
86. Heusch P, Aker S, Boengler K, Deindl E, van de Sand A, Klein K, et al. (2010). Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation. Am J Physiol Heart Circ Physiol 299: H446-H453.
87. Hinz B, Kuntze U, Schröder H, (1998). Pentaerithrityl tetranitrate and its phase I metabolites are potent activators of cellular cyclic GMP accumulation. Biochem Biophys Res Commun 253: 658-661.
88. Horowitz JD, Heresztyn T, (2007). An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci 851: 42-50.
89. Hovsepian E, Penas F, Goren NB, (2010). 15-deoxy-Delta12,14 prostaglandin GJ2 but not rosiglitazone regulates metalloproteinase 9, NOS-2, and cyclooxygenase 2 expression and functions by peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms in cardiac cells. Shock 34: 60-67.
90. Huang PL, (2009). eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 20: 295-302.
91. Ignarro LJ, Napoli C, Loscalzo J, (2002). Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 90: 21-28.
92. Ikeda U, Shimpo M, Ikeda M, Minota S, Shimada K, (2001). Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J Cardiovasc Pharmacol 38: 69-77.
93. Ito H, Torii M, Suzuki T, (1995). Decreased superoxide dismutase activity and increased superoxide anion production in cardiac hypertrophy of spontaneously hypertensive rats. Clin Exp Hypertens 17: 803-816.
94. Jesmin S, Zaedi S, Maeda S, Yamaguchi I, Goto K, Miyauchi T, (2006). Effects of a selective endothelin a receptor antagonist on the expressions of iNOS and eNOS in the heart of early streptozotocin-induced diabetic rats. Exp Biol Med 231: 925-931.
95. Jin CZ, Jang JH, Wang Y, Kim JG, Bae YM, Shi J, et al. (2012). Neuronal nitric oxide synthase is up-regulated by angiotensin II and attenuates NADPH oxidase activity and facilitates relaxation in murine left ventricular myocytes. J Mol Cell Cardiol 52: 1274-1278.
96. Jo H, Otani H, Jo F, Shimazu T, Okazaki T, Yoshioka K, et al. (2011). Inhibition of nitric oxide synthase uncoupling by sepiapterin improves left ventricular function in streptozotocin-induced diabetic mice. Clin Exp Pharmacol Physiol 38: 485-493.
97. Jozefowicz E, Brisson H, Rozenberg S, Mebazaa A, Gelé P, Callebert J, et al. (2007). Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats. Crit Care Med 35: 856-863.
98. Kapoor A, Collino M, Castiglia S, Fantozzi R, Thiemermann C, (2010). Activation of peroxisome proliferator-activated receptor-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat. Shock 34: 117-124.
99. Kardassis D, Bech-Hanssen O, Schönander M, Sjöström L, Petzold M, Karason K, (2012). Impact of body composition, fat distribution and sustained weight loss on cardiac function in obesity. Int J Cardiol 159: 128-133.
100. Kass DA, Takimoto E, Nagayama T, Champion HC, (2007). Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res 75: 303-314.
101. Kassan M, Galán M, Partyka M, Saifudeen Z, Henrion D, Trebak M, et al. (2012). Endoplasmic reticulum stress is involved in cardiac damage and vascular endothelial dysfunction in hypertensive mice. Arterioscler Thromb Vasc Biol 32: 1652-1661.
102. Knowles CJ, Dionne M, Cebova M, Pinz IM, (2011). Palmitate-induced translocation of caveolin-3 and endothelial nitric oxide synthase in cardiomyocytes. OnLine J Biol Sci 11: 27-36.
103. Knowles CJ, Cebova M, Pinz IM, (2013). Palmitate diet-induced loss of cardiac caveolin-3: a novel mechanism for lipid-induced contractile dysfunction. PLoS ONE 8: e61369.
104. Koh KK, Park SM, Quon MJ, (2008). Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 117: 3238-3249.
105. Kojda G, Stein D, Kottenberg E, Schnaith EM, Noack E, (1995). In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5 mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol 25: 763-773.
106. Kojda G, Hacker A, Noack E, (1998). Effects of nonintermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and superoxide production. Eur J Pharmacol 355: 23-31.
107. Koka S, Das A, Salloum FN, Kukreja RC, (2013). Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. Free Radic Biol Med 60: 80-88.
108. Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S, et al. (2000). Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J 139: 1081-1087.
109. Kristek F, Gerová M, (1996). Long-term NO synthase inhibition affects heart weight and geometry of coronary and carotid arteries. Physiol Res 45: 361-367.
110. Kristek F, Fáberová V, Varga I, (2003). Long-term effect of molsidomine and pentaerythrityl tetranitrate on cardiovascular system of spontaneously hypertensive rats. Physiol Res 52: 709-717.
111. Kupai K, Csonka C, Fekete V, Odendaal L, van Rooyen J, de Marais W, et al. (2009). Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. Am J Physiol Heart Circ Physiol 297: H1729-H1735.
112. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. (2003). Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201-1209.
113. Larson JE, Rainer PP, Watts VL, Yang R, Miller KL, Phan A, et al. (2012). Dependence of β3-adrenergic signaling on the adipokine leptin in cardiac myocytes. Int J Obes 36: 876-879.
114. Laskowski A, Woodman OL, Cao AH, Drummond GR, Marshall T, Kaye DM, et al. (2006). Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 72: 112-123.
115. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d'Amati G, et al. (2000). Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 49: 293-297.
116. Li H, Wallerath T, Munzel T, Forstemann U, (2002). Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 7: 149-164.
117. Ljubkovic M, Shi Y, Cheng Q, Bosnjak Z, Jiang MT, (2007). Cardiac mitochondrial ATP-sensitive potassium channel is activated by nitric oxide in vitro. FEBS Lett 581: 4255-4259.
118. Lombardi C, Castrini AI, Metra M, Carubelli V, Lazzarini V, Inama L, et al. (2012). Efficacy of ACE inhibitors in patients with recent myocardial infarction. Studies with zofenopril. G Ital Cardiol 13 (10 Suppl. 2): 55S-58S.
119. Madonna R, Di Napoli P, Massaro M, Grilli A, Felaco M, De Caterina A, et al. (2005). Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J Biol Chem 280: 13503-13511.
120. Maffei A, Aretini A, Vecchione C, Poulet R, Marino G, Gentile MT, et al. (2006). Characterization of nitric oxide release by nebivolol and its metabolites. Am J Hypertens 19: 579-586.
121. Maffei A, Di Pardo A, Carangi R, Carullo P, Poulet R, Gentile MT, et al. (2007). Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension 50: 652-656.
122. Makino N, Maeda T, Oyama J, Higuchi Y, Mimori K, (2009). Improving insulin sensitivity via activation of PPAR-gamma increases telomerase activity in the heart of OLETF rats. Am J Physiol Heart Circ Physiol 297: H2188-H2195.
123. Maksimenko AV, Vavaev AV, (2012). Antioxidant enzymes as potential targets in cardioprotection and treatment of cardiovascular diseases. Enzyme antioxidants: the next stage of pharmacological counterwork to the oxidative stress. Heart Int 7: e3.
124. Matheeussen V, Waumans Y, Martinet W, Van Goethem S, Van der Veken P, Scharpé S, et al. (2013). Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Res Cardiol 108: 350.
125. Megson IL, Leslie SJ, (2009). La-419, a nitric-oxide donor for the treatment of cardiovascular disorders. Curr Opin Investig Drugs 10: 276-285.
126. Mendez M, LaPointe MC, (2003). PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 42: 844-850.
127. Merla R, Ye Y, Lin Y, Manickavasagam S, Huang MH, Perez-Polo RJ, et al. (2007). The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol 293: H1918-H1928.
128. Michel T, (2010). The complexities of coupling nitric oxide synthase pathways in the heart. Circulation 121: 484-486.
129. Miller MW, Knaub LA, Olivera-Fragoso LF, Keller AC, Balasubramaniam V, Watson PA, et al. (2013). Nitric oxide regulates vascular adaptive mitochondrial dynamics. Am J Physiol Heart Circ Physiol 304: H1624-H1633.
130. Mollnau H, Oelze M, August M, Wendt M, Daiber A, Schulz E, et al. (2005). Mechanisms of increased vascular superoxide production in an experimental model of idiopathic dilated cardiomyopathy. Arterioscler Thromb Vasc Biol 25: 2554-2559.
131. Munzel T, Sayegh H, Freeman BA, Hink U, Matheis E, Hartmann M, (1995). Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95: 187-194.
132. Münzel T, Daiber A, Ullrich V, Mülsch A, (2005). Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol 25: 1551-1557.
133. Münzel T, Gori T, Bruno RM, Taddei S, (2010). Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 31: 2741-2749.
134. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T, (2007). Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 50: 877-883.
135. Nakano A, Liu GS, Heusch G, Downey JM, Cohen MV, (2000). Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. J Mol Cell Cardiol 32: 1159-1167.
136. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, et al. (2004). Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 148: e5.
137. Nduhirabandi F, du Toit EF, Lochner A, (2012). Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? Acta Physiol 205: 209-223.
138. Nickola MW, Wold LE, Colligan PB, Wang GJ, Samson WK, Ren J, (2000). Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 36: 501-505.
139. Okazaki T, Otani H, Shimazu T, Yoshioka K, Fujita M, Katano T, et al. (2011). Reversal of inducible nitric oxide synthase uncoupling unmasks tolerance to ischemia/reperfusion injury in the diabetic rat heart. J Mol Cell Cardiol 50: 534-544.
140. Oliveira HC, Cosso RG, Alberici LC, Maciel EN, Salerno AG, Dorighello GG, et al. (2005). Oxidative stress in atherosclerosis-prone mouse is due to low antioxidant capacity of mitochondria. FASEB J 19: 278-280.
141. Onody A, Csonka C, Giricz Z, Ferdinandy P, (2003). Hyperlipidemia induced by a cholesterol-rich diet leads to enhanced peroxynitrite formation in rat hearts. Cardiovasc Res 58: 663-670.
142. Ou ZJ, Chang FJ, Luo D, Liao XL, Wang ZP, Zhang X, et al. (2011). Endothelium-derived microparticles inhibit angiogenesis in the heart and enhance the inhibitory effects of hypercholesterolemia on angiogenesis. Am J Physiol Endocrinol Metab 300: E661-E668.
143. Ozakca I, Arioglu-Inan E, Esfahani H, Altan VM, Balligand JL, Kayki-Mutlu G, et al. (2013). Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockage. Am J Physiol Heart Circ Physiol 304: H1267-H1276.
144. Pacher P, Szabõ C, (2005). Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal 7: 1568-1580.
145. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabõ E, Szabõ C, (2002). The role of poly (ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51: 514-521.
146. Pacher P, Obrosova IG, Mabley JG, Szabõ C, (2005). Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 12: 267-275.
147. Pacher P, Beckman JS, Liaudet L, (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424.
148. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
149. Pechánová O, (2007). Contribution of captopril thiol group to the prevention of spontaneous hypertension. Physiol Res 56 (Suppl. 2): S41-S48.
150. Pechánová O, Bernátová I, Babál P, Martínez MC, Kyselá S, Stvrtina S, et al. (2004). Red wine polyphenols prevent cardiovascular alterations in L-NAME-induced hypertension. J Hypertens 22: 1551-1559.
151. Pechánová O, Zicha J, Kojsová S, Dobesová Z, Jendeková L, Kunes J, (2006). Effect of chronic N-acetylcysteine treatment on the development of spontaneous hypertension. Clin Sci 110: 235-242.
152. Pechánová O, Zicha J, Paulis L, Zenebe W, Dobesová Z, Kojsová S, et al. (2007). The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol 561: 129-136.
153. Pechanova O, Simko F, (2009). Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J Hypertens 27: S32-S36.
154. Pechanova O, Simko F, (2010). The role of nuclear factor kappa B and nitric oxide interaction in heart remodelling. J Hypertens 28 (Suppl. 1): S39-S44.
155. Pechanova O, Bernatova I, Pelouch V, Simko F, (1997). Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 29: 3365-3374.
156. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL, (2003). Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 107: 2480-2486.
157. Penumathsa SV, Thirunavukkarasu M, Zhan L, Maulik G, Menon VP, Bagchi D, et al. (2008). Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med 12: 2350-2361.
158. Penumathsa SV, Thirunavukkarasu M, Samuel SM, Zhan L, Maulik G, Bagchi M, et al. (2009). Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury. Biochim Biophys Acta 1792: 39-48.
159. Peters A, Schweiger U, Frühwald-Schultes B, Born J, Fehm HL, (2002). The neuroendocrine control of glucose allocation. Exp Clin Endocrinol Diabetes 110: 199-211.
160. Poon BY, Raharjo E, Patel KD, Tavener S, Kubes P, (2003). Complexity of inducible nitric oxide synthase: cellular source determines benefit versus toxicity. Circulation 108: 1107-1112.
161. Post H, Schulz R, Behrends M, Gres P, Umschlag C, Heusch G, (2000). No involvement of endogenous nitric oxide in classical ischemic preconditioning in swine. J Mol Cell Cardiol 32: 725-733.
162. Post H, Schulz R, Gres P, Heusch G, (2001). No involvement of nitric oxide in the limitation of beta-adrenergic inotropic responsiveness during ischemia. Am J Physiol Heart Circ Physiol 281: H2392-H2397.
163. Poudyal H, Campbell F, Brown L, (2010). Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr 40: 946-953.
164. Puthanveetil P, Zhang D, Wang Y, Wang F, Wan A, Abrahani A, et al. (2012). Diabetes triggers a PARP1 mediated death pathway in the heart through participation of FoxO1. J Mol Cell Cardiol 53: 677-686.
165. Radovits T, Bömicke T, Kökény G, Arif R, Loganathan S, Kécsán K, et al. (2009). The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br J Pharmacol 156: 909-919.
166. Rafighi Z, Shiva A, Arab S, Mohd Yousof R, (2013). Association of dietary vitamin C and e intake and antioxidant enzymes in type 2 diabetes mellitus patients. Glob J Health Sci 5: 183-187.
167. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, et al. (2005). Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 91: 806-810.
168. Rajesh M, Mukhopadhyay P, Bátkai S, Mukhopadhyay B, Patel V, Haskõ G, et al. (2009). Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med 13: 2330-2341.
169. Rajesh M, Bátkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horváth B, et al. (2012). Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 61: 716-727.
170. Rassaf T, Poll LW, Brouzos P, Lauer T, Totzeck M, Kleinbongard P, et al. (2006). Positive effects of nitric oxide on left ventricular function in humans. Eur Heart J 27: 1699-1705.
171. Rassaf T, Ferdinandy P, Schulz R, (2014). Nitrite in organ protection. Br J Pharmacol 171: 1-11.
172. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, et al. (2011). Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 124: 1107-1117.
173. Reiter RJ, Tan DX, Korkmaz A, (2009). The circadian melatonin rhythm and its modulation: possible impact on hypertension. J Hypertens 27 (Suppl. 6): S17-S21.
174. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH, (2003). B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: importance of cyclic GMP. Diabetes 52: 2389-2395.
175. Ruiz-Hurtado G, Delgado C, (2010). Nitric oxide pathway in hypertrophied heart: new therapeutic uses of nitric oxide donors. J Hypertens 28: S56-S61.
176. Ruiz-Hurtado G, Fernandez-Velasco M, Mourelle M, Delgado C, (2007). La419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension 50: 1049-1056.
177. Saraiva RM, Minhas KM, Zheng M, Pitz E, Treuer A, Gonzalez D, et al. (2007). Reduced neuronal nitric oxide synthase expression contributes to cardiac oxidative stress and nitroso-redox imbalance in ob/ob mice. Nitric Oxide 16: 331-338.
178. Schwemmer M, Sommer O, Bassenge E, (2000). Blockade of angiotensin signaling improves myocardial function in hypercholesterolemia independent of changes in eicosanoid release. Cardiovasc Drugs Ther 14: 317-327.
179. Shah AM, MacCarthy PA, (2000). Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 86: 49-86.
180. Simko F, Pechanova O, (2010). Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens 28 (Suppl. 1): S1-S6.
181. Smith JM, Paulson DJ, Romano FD, (1997). Inhibition of nitric oxide synthase by L-NAME improves ventricular performance in streptozotocin-diabetic rats. J Mol Cell Cardiol 29: 2393-2402.
182. Stasch JP, Pacher P, Evgenov OV, (2011). Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123: 2263-2273.
183. Stockklauser-Färber K, Ballhausen T, Laufer A, Rösen P, (2000). Influence of diabetes on cardiac nitric oxide synthase expression and activity. Biochim Biophys Acta 1535: 10-20.
184. Stokes KY, Dugas TR, Tang Y, Garg H, Guidry E, Bryan NS, (2009). Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses endothelial dysfunction. Am J Physiol Heart Circ Physiol 296: H1281-H1288.
185. Sutra T, Oiry C, Azay-Milhau J, Youl E, Magous R, Teissèdre PL, et al. (2008). Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. J Agric Food Chem 56: 11683-11687.
186. Swynghedauw B, (1999). Molecular mechanisms of myocardial remodeling. Physiol Rev 79: 215-262.
187. Tang L, Wang H, Ziolo MT, (2013). Targeting NOS as a therapeutic approach for heart failure. Pharmacol Ther S0163-7258: 00255-6. [Epub ahead of print].
188. Tirziu D, Simons M, (2008). Endothelium-driven myocardial growth or nitric oxide at the crossroads. Trends Cardiovasc Med 18: 299-305.
189. Toblli J, Cao G, Rivas C, Munoz M, Giani J, Dominici F, et al. (2010). Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. J Hypertens 28: 1007-1019.
190. Tribulova N, Ravingerova T, Okruhlicova L, Gabauer I, Fickova M, Pancza D, et al. (2000). Modulation of cAMP level by tedisamil in guinea pig heart. Mol Cell Biochem 210: 75-80.
191. Tsai TH, Chai HT, Sun CK, Yen CH, Leu S, Chen YL, et al. (2012). Obesity suppresses circulating level and function of endothelial progenitor cells and heart function. J Transl Med 10: 137.
192. Turko IV, Marcondes S, Murad F, (2001). Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol 281: H2289-H2294.
193. Varga ZV, Kupai K, Szcs G, Gáspár R, Pálõczi J, Faragõ N, et al. (2013). MicroRNA-25-dependent up-regulation of NADPH oxidase 4 (NOX4) mediates hypercholesterolemia-induced oxidative/nitrative stress and subsequent dysfunction in the heart. J Mol Cell Cardiol 62: 111-121.
194. Varma A, Das A, Hoke NN, Durrant DE, Salloum FN, Kukreja RC, (2012). Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS ONE 7: e45243.
195. Vrankova S, Barta A, Parohova J, Pechanova O, (2009). Could NF-kappa B play a role in blood pressure regulation? Focused on L-NAME-induced hypertension. J Hypertens 27 (Suppl. 4): S140.
196. Wang XF, Zhang JY, Li L, Zhao XY, Tao HL, Zhang L, (2011). Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. Clin Exp Pharmacol Physiol 38: 94-101.
197. Ward NC, Croft KD, (2006). Hypertension and oxidative stress. Clin Exp Pharmacol Physiol 33: 872-876.
198. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, et al. (2002). Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16: 1027-1040.
199. Widder JD, Fraccarollo D, Galuppo P, Hansen JM, Jones DP, Ertl G, et al. (2009). Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. Hypertension 54: 338-344.
200. Wilcox CS, (2010). Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther 126: 119-145.
201. Wu G, (2009). Amino acids: metabolism, functions, and nutrition. Amino Acids 37: 1-17.
202. Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, et al. (2009). Arginine metabolism and nutrition in growth, health and disease. Amino Acids 37: 153-168.
203. Xiao X, Su G, Brown SN, Chen L, Ren J, Zhao P, (2010). Peroxisome proliferator-activated receptors gamma and alpha agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase. J Nutr Biochem 21: 621-626.
204. Ye Y, Lin Y, Manickavasagam S, Perez-Polo JR, Tieu BC, Birnbaum Y, (2008a). Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol 295: H2436-H2446.
205. Ye Y, Martinez JD, Perez-Polo RJ, Lin Y, Uretsky BF, Birnbaum Y, (2008b). The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 295: H343-H351.
206. Young ME, Guthrie PH, Razeghi P, Leighton B, Abbasi S, Patil S, et al. (2002). Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 51: 2587-2595.
207. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K, et al. (2004). Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 44: 904-913.
208. Yue ZJ, Yu ZB, (2011). Cardioprotection by the inhibitory effect of nitric oxide. Sheng Li Xue Bao 63: 191-197.
209. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P, (2000). Vitamin E supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 154-160.
210. Zakula Z, Koricanac G, Tepavcevic S, Stojiljkovic M, Milosavljevic T, Isenovic ER, (2011). Impairment of cardiac insulin signaling in fructose-fed ovariectomized female Wistar rats. Eur J Nutr 50: 543-551.
211. Zanfolin M, Faro R, Araujo EG, Guaraldo AM, Antunes E, De Nucci G, (2006). Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol 47: 391-395.
212. Zaobornyj T, Ghafourifar P, (2012). Strategic localization of heart mitochondrial NOS: a review of the evidence. Am J Physiol Heart Circ Physiol 303: H1283-H1293.
213. Zhang DX, Zou AP, Li PL, (2003). Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries. Am J Physiol Heart Circ Physiol 284: H605-H612.
214. Zhang FJ, Ma LL, Wang WN, Qian LB, Yang MJ, Yu J, et al. (2012). Hypercholesterolemia abrogates sevoflurane-induced delayed preconditioning against myocardial infarct in rats by alteration of nitric oxide synthase signaling. Shock 37: 485-491.
215. Zhang H, Morgan B, Potter BJ, Ma L, Dellsperger KC, Ungvari Z, et al. (2010). Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol 299: H985-H994.
216. Zhang Y, Janssens SP, Wingler K, Schmidt HH, Moens AL, (2011). Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. Am J Physiol Heart Circ Physiol 301: H634-H646. Erratum in: Am J Physiol Heart Circ Physiol (2012) 303(2): H241.
217. Zhen J, Lu H, Wang XQ, Vaziri ND, Zhou XJ, (2008). Upregulation of endothelial and inducible nitric oxide synthase expression by reactive oxygen species. Am J Hypertens 21: 28-34.
218. Zhou MS, Schulman IH, Raij L, (2004). Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 24: 366-378.
219. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, et al. (2000). Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97: 1784-1789.
220. Zou MH, Shi C, Cohen RA, (2002). Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 109: 817-826.